Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET

Company Participants

Karen Hunady - Director-Corporate Communications & Investor Relations

Nancy Simonian - President & Chief Executive Officer

David Roth - Chief Medical Officer

Jason Haas - Chief Financial Officer

Conference Call Participants

Edward Tenthoff - Piper Sandler

Philip Nadeau - Cowen

Operator

Good day, and welcome to the Q3 2022 Syros Pharmaceuticals, Inc. Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker Ms. Karen Hunady, Director of Corporate Communications and Investor Relations. Please go ahead.

Karen Hunady

Thank you. This morning we issued a press release announcing our third quarter 2022 financial results and a broader business update. The release is available on the Investor and Media section of the Syros’ website at www.syros.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas our Chief Financial Officer. We will then open the call for questions. Kristen Stephens, our Chief Development Officer; Dr. Eric Olson, our Chief Scientific Officer; and Conley Chee, our Chief Commercial Officer are also on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual report on Form 10-K and our quarterly report on Form 10-Q that we filed this morning, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

I would now like to turn the call over to Nancy.

Nancy Simonian

Thank you, Karen. Good morning, everyone and thank you for joining us today. The third quarter was transformative for Syros. In September, we announced the concurrent close of our merger with TYME Technologies and our oversubscribed Pipe financing. Together these transactions netted approximately $190 million, providing us the necessary cash to continue investing in the clinical development of our late stage targeted hematology programs, while also supporting initial launch readiness.